Pursuit of Group Synergies
First written in FY2017. 14 of 16 entries say "Advanced", first in FY2018-Q2. Latest entry: 2026-08-07.
The whole theme swung hardest in 2025: 1 of 7 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「We will use the pharmacy business's expertise in the information provided by medical representatives to deliver information from the perspective of patients and healthcare professionals and expand our market share.」
We are using the pharmacy business's expertise in the information provided by pharmaceutical-industry medical representatives to expand market share through synergies between businesses. - FY2025-H1AdvancedAnnual report
「Going forward, we will continue to leverage synergies with the pharmacy and BPO businesses while focusing exclusively on pharmaceuticals to achieve further growth toward our medium-term targets.」
Following the consolidation of Daiichi Sankyo Espha Co., Ltd. as a subsidiary, a growth strategy was presented that combines the use of synergies with the pharmacy and BPO businesses and a focus on pharmaceuticals. - FY2024-Q3RestatedAnnual report
「The purpose of this acquisition is to contribute to healthcare and business development by sharing information and expertise between Daiichi Sankyo Espha Co., Ltd. and our group, developing high-value-added pharmaceuticals, and creating products that meet customer needs, particularly those of AG.」
We continue to pursue synergies by sharing information and expertise with Daiichi Sankyo Espha Co., Ltd., developing products centered on AG, and integrating the businesses of the two companies. - FY2024-Q2AdvancedAnnual report
「We are also working to realize synergies from bringing Daiichi Sankyo Espha Co., Ltd. into the group.」
Following completion of the acquisition of a 30% stake in Daiichi Sankyo Espha Co., Ltd., initiatives to realize synergies from bringing the company into the group were presented. - FY2024-Q1AdvancedAnnual report
「The purpose of this acquisition is to contribute to healthcare and business development by sharing information and expertise between Daiichi Sankyo Espha Co., Ltd. and our group, developing high-value-added pharmaceuticals, and creating products that meet customer needs, particularly those of AG.」
A specific plan for group synergies was presented, aimed at developing high-value-added pharmaceuticals and creating AG products through the sharing of information and expertise with Daiichi Sankyo Espha Co., Ltd. - FY2022-Q1AdvancedAnnual report
「In the pharmaceutical manufacturing and marketing business, sales from co-promotion with major partner pharmaceutical companies have remained strong.」
Synergies between businesses and companies from the pharmaceutical manufacturing and marketing business and joint promotions with partner pharmaceutical companies are reflected in sales. - FY2021AdvancedAnnual report
「In the pharmaceutical manufacturing and marketing business, we improved profitability by promoting sales of our own products through our insurance pharmacies, conducting joint promotions with major partner pharmaceutical companies, and handling investigational drugs.」
We achieved improved profitability through sales of our own products at insurance pharmacies, joint promotions with partner pharmaceutical companies, and the handling of investigational drugs, creating synergies between businesses and companies. - FY2021-Q3AdvancedAnnual report
「In the pharmaceutical manufacturing and marketing business, we improved profitability by promoting sales of our own products through our insurance pharmacies, conducting joint promotions with major partner pharmaceutical companies, and handling investigational drugs.」
We have put synergies between businesses and companies into practice through sales of our own products at insurance pharmacies, joint promotions with partner pharmaceutical companies, and the handling of investigational drugs. - FY2020AdvancedAnnual report
「In its pharmacy operations, while promoting the use of generic drugs after achieving the government's required 80% usage rate, the company pursued group synergies, including by actively using products from 藤永製薬株式会社.」
The company put into practice synergies between its health insurance pharmacy business and pharmaceutical manufacturing and marketing business by promoting the use of generic drugs and actively using 藤永製薬 products in its pharmacies. - FY2020-Q3AdvancedAnnual report
「Going forward, the group will enhance synergies among its 3 businesses, establish an end-to-end service spanning pharmaceutical manufacturing through delivery to patients, and pursue its goal of becoming a comprehensive healthcare company.」
The company has expanded the scope of group synergies to three businesses: health insurance pharmacies, BPO, and pharmaceutical manufacturing and marketing, and is aiming to establish an end-to-end service. - FY2019-Q3AdvancedAnnual report
「As of 9 November 2018, the company had brought 株式会社SPLENDID, which provides medicommi, a web-based medical information platform emphasizing accuracy under physician supervision, into the group, and will continue pursuing further group synergies.」
The company brought 株式会社SPLENDID into the group and advanced the pursuit of group synergies by adding a web-based medical information media business. - FY2019-Q2AdvancedAnnual report
「The Company transitioned to a holding company structure effective 1 October 2018 and aims to (1) strengthen the function for advancing group management strategies, (2) accelerate decision-making by clarifying authority and responsibility, (3) strengthen corporate governance with an emphasis on the compliance management framework, and (4) maximize group synergies.」
The company transitioned to a holding company structure and established a concrete organizational foundation for strengthening the group's management strategy functions and maximizing synergies. - FY2018-Q2AdvancedAnnual report
「By transitioning to a holding company structure, we aim to (1) strengthen the function for advancing group management strategies, (2) accelerate decision-making by clarifying authority and responsibility, (3) strengthen corporate governance with an emphasis on the compliance management framework, and (4) maximize group synergies.」
The company decided to transition to a holding company structure as a means of strengthening the group's management strategy functions and maximizing group synergies. - FY2017First statedAnnual report
「To secure a stable earnings base amid increasingly challenging industry conditions, the group will share management strategies across its companies, generate synergies, and achieve an optimal business portfolio.」
The company has stated that sharing strategies among group companies and generating synergies is a medium- to long-term strategy.